Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668095 | 1.00 | ABCB1 (0.38) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL668634 | 0.94 | ABCB1 (0.36) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL29684859 | 0.94 | ABCB1 (0.36) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL2683648 | 0.94 | ABCB1 (0.36) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL18091873 | 0.92 | NPC1 (0.39) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL29684694 | 0.91 | ABCB1 (0.39) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL667409 | 0.91 | ABCB1 (0.39) | ABCB1SMN1; SMN2CYP3A4ALDH1A1NPC1 | |
| SCHEMBL29684822 | 0.89 | PLK1 (0.39) | ABCB1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL667456 | 0.89 | PLK1 (0.39) | ABCB1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL7479127 | 0.88 | ABCB1 (0.39) | ABCB1ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406655-A | Modulation of expression of polypeptides by novel gene switch expression systems | 普瑞赛格恩公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118159653-A | Chimeric receptor therapies | 普雷西根公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4274898-A2 | CHIMERIC RECEPTOR THERAPY | Precigen, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4251278-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | Precigen, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022150732-A2 | CHIMERIC RECEPTOR THERAPY | PRECIGEN, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022115470-A1 | HUMAN PAPILLOMA VIRUS VACCINES AND USES OF THE SAME FOR HPV ASSOCIATED DISEASES | PRECIGEN, INC. (US) | 2022-06-02 | — | — | WO | disclosed |